Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10158097" target="_blank" >RIV/00098892:_____/23:10158097 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00131333 RIV/61989592:15110/23:73620447 RIV/65269705:_____/23:00079138
Result on the web
<a href="https://haematologica.org/article/view/haematol.2022.282263" target="_blank" >https://haematologica.org/article/view/haematol.2022.282263</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2022.282263" target="_blank" >10.3324/haematol.2022.282263</a>

Result language
angličtina
Original language name
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
Original language description
For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the approach to the treatment of AML has shifted significantly toward the use of novel and effective, target-directed therapies, including the anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and an inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin. Our study's major strength is its unique focus on a homogeneous cohort of patients with FLT3-mutated/CD33+ AML treated with GO + midostaurin + IC at two academic hematology centers. The study limitations concern only the small number of evaluated cases. In summary, our data highlighted a high response rate and good tolerability with no evidence of increased toxicity (with the exception of slightly prolonged recovery of neutrophil count) of GO plus midostaurin added to standard IC in patients with newly diagnosed FLT3-mutated/CD33+ AML. Our results should be validated in a larger group of patients with a longer follow-up.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)